We have created a system in which synthetically produced novel bioactive peptides can be expressed in vivo in Escherichia coli. Twenty thousand of these peptides were screened and 21 inhibitors were found that could inhibit the growth of E. coli on minimal media. The inhibitors could be placed into one of two groups, 1-day inhibitors, which were
partially inhibitory, and 2-day inhibitors, which were completely inhibitory. Sequence analysis showed that two of the most potent inhibitors were actually peptide±protein chimeras in which the peptides had become fused to the 63 amino acid Rop protein which was also contained in the expression vector used in this study. Given that Rop is known to form an incredibly stable structure, it could be serving as a stabilizing motif for these peptides. Sequence analysis of the predicted coding regions from the next 10 most inhibitory peptides showed that four of the 10 peptides contained one or more proline residues either at or very near the C-terminal end of the peptide which could act to prevent degradation by peptidases. Collectively, based on what we observed in our screen of synthetic bioactive peptides that could prevent the growth of E. coli and what has been learned from structural studies of naturally occurring bioactive peptides, the presence of a stabilizing motif seems to be important for small peptides, if they are to be biologically active.
Abbreviations: IPTG, isopropyl b-D-thiogalactoside.
Bioactive peptides are small peptides that elicit a biological activity. Over 500 of these peptides, which average 20 amino acids in size, have now been identi®ed and characterized (1±3). They have been isolated in a variety of systems, exhibit a wide range of actions, and have been utilized as therapeutic agents in the ®eld of medicine, as well as diagnostic tools in both basic and applied research. Some of the better known peptides employed as therapeutic agents include calcitonin, gastrin, glucagon, luteinizing hormone releasing factor, oxytocin, secretin, somatostatin and vasopressin (4) .
Where the mode of action of these peptides has been determined, it has been found to be due to the interaction of the bioactive peptide with a speci®c protein target (5) .
In most cases, the bioactive peptide acts by binding to and inactivating its protein target with incredibly high speci®city. Binding constants of these peptides for their protein targets typically have been determined to be in the nm range (1,2) with binding constants as high as 10 ±12 m being reported (6,7).
There has been an increasing interest in employing synthetically derived bioactive peptides as novel pharmaceutical agents due to the inherent ability of these peptides to bind to and inhibit speci®c protein targets (8±10). Three obvious areas in which synthetically produced peptides could be utilized are in the development of new antibacterial, antiviral and anticancer agents. To develop antibacterial or antiviral agents, synthetically derived peptides would be isolated which could either bind to and prevent bacterial or viral surface proteins from interacting with their host cell receptors, or else prevent the action of speci®c toxin or protease proteins. To develop anticancer agents, synthetically derived peptides would be isolated which could bind to and prevent the action of speci®c oncogenic proteins.
Researchers have been engineering novel bioactive peptides through the use of two different in vitro approaches.
The ®rst approach involves the chemical synthesis of a randomized library of 6±10 amino acid peptides (8, 9, 11) . In the second approach, a randomized oligonucleotide library is cloned into a Ff ®lamentous phage gene which allows peptides that are 6±38 amino acids in length to be expressed on the surface of the bacteriophage (10, 12 
Experimental Procedures

Media
Rich Luria-Bertani and minimal M9 media used in this study was prepared as described by Miller (13) . Ampicillin was used in rich media at a ®nal concentration of 100 mg/mL and in minimal media at a ®nal concentration of 50 mg/mL.
Isopropyl b-d-thiogalactoside (IPTG) was added to media at a ®nal concentration of 1 mm.
Bacterial strains and plasmids
ALS225 which is MC1061/F'lacI q1 Z+Y+A+ was the E. coli strain used in this study (14) . The genotype for MC1061 is araD139 D(araABOIC-leu)7679 D(lac)X74 galU galK rpsL hsr-hsm+ (15) . pLAC11 is the highly regulable expression vector that was used in this work (14) .
Generating the randomized peptide library 
Secondary structure predictions
The propensity for the inhibitor peptides to form a-helixes or b-sheets was initially considered using both Chou and
Fasman (16, 17) and Garnier, Osguthorpe, and Robson analysis (18, 19 ). The peptide sequences were then analyzed using the peptool protein structure software package from BioTools Inc. The membrane spanning domain in pPep6 was analyzed using AMPHI (20) , SOAP (21), SOSUI (22) and
TMpredict (23) 
Chemicals and reagents
Extension reactions were carried out using Klenow from New England Biolabs while ligation reactions were performed using T4 DNA Ligase from Life Sciences. IPTG was obtained from Diagnostic Chemicals Limited.
Results
Construction of the peptide library
In order to isolate potential inhibitor peptides, a totally randomized oligonucleotide library that encoded up to 20 amino acid peptides was cloned into the pLAC11 expression vector (14) as shown in Fig. 1 and transformed Figure 1 . Scheme for generating the randomized 20 amino acid peptide library in vivo. The complementary strand of the 93 bp randomized oligonucleotide is generated by ®lling-in with Klenow using the 18 bp oligonucleotide primer. The resulting ds-DNA is digested with BglII and EcoRI, and then ligated into the pLAC11 expression vector which has also been digested with the same two restriction enzymes. Wherever an`X' occurs in the oligonucleotide, a random mixture of all four of the nucleotides, A, C, G and T, is used.
into E. coli under repressed conditions. Most of the routinely employed expression vectors such as pKK223-3, pKK233-2, pTrc99A and the pET series produce signi®cant amounts of protein from cloned genes even when grown under repressed conditions (25, 26) . We were concerned that we might not be able to clone potent inhibitor peptides unless we were able to isolate them under completely repressed conditions. For this reason, we chose to use the highly regulable pLAC11 expression vector for our studies.
Because encoded peptides that are expressed using pLAC11
are under the control of the wild-type lac operon, their expression can be turned on or off by the presence or absence of the gratuitous inducer, IPTG.
Researchers employing the fusion-phage technology, which also utilizes oligonucleotides to encode randomized 
Identifying and characterizing inhibitor peptides from the library
Using a grid-patching technique in which the clones were patched onto both rich repressing plates and minimal inducing plates, we screened 20,000 potential candidates.
Minimal medium, which imposes more stringent growth demands on the cell, was chosen for the screen in order to maximize the number of inhibitors that could be found. It is well known that growth in minimal media puts more demands on a bacterial cell than growth in rich media, as evidenced by the drastically reduced growth rate, and thus a peptide that adversely affects cell growth would be more likely detected on minimal media. We isolated 21 IPTGdependent inhibitors in this screen and found that they could be categorized into two classes based on their inhibitory properties on plates. One-day inhibitors either showed no or very little growth after 24 h, but showed signi®cant growth after 48 h. Two-day inhibitors were completely inhibitory and showed no growth for a full 48 h. Growth rates were determined as the spectrophotometric Figure 2 . A minimal inducing plate showing the difference between a 1-and 2-day inhibitor. Shown here is a minimal inducing plate that contains both a 1-day and a 2-day inhibitor, photographed at 24 and 48 h. The 2-day inhibitor on row three from the top of the plate is completely inhibitory and does not grow at either 24 or 48 h. The 1-day inhibitor on row seven from the top of the plate does not grow at 24 h but does grow at 48 h.
Walker et al . Novel bioactive peptides that inhibit the growth of E. coli change in A 550 per unit time within the log phase of growth.
The inhibition of the growth rate was then calculated for the inhibitors using pLAC11 as a control. As indicated in Table 1 , the 1-day inhibitors inhibited the bacterial growth rate at an average of 25%, whereas the 2-day inhibitors inhibited the bacterial growth rate at an average of 75%.
The hypothetical data in Table 2 These calculations are consistent with the fact that 2-day inhibitors prevent the growth of bacteria on plates for a full 48 h, whereas the 1-day inhibitors only prevent the growth of bacteria on plates for 24 h.
In order to continue our analysis, we next wanted to verify that all of the candidates contained 66 bp inserts as expected (Fig. 1) . Although most of them did, two of our most potent 2-day inhibitors, pPep3 and pPep14, vector (14) .
Sequence analysis of the top 10 anchorless inhibitor peptides
The top 10 anchorless inhibitor peptides were sequenced and their coding sequences determined (Table 3) The characteristics of the predicted coding regions of the inhibitor peptides proved to be quite interesting. Three of the 10 peptides, pPep1, pPep13 and pPep17, contained a proline residue as their last amino acid. In addition, one of the peptides, pPep12, contained two proline residues at the n ± 2 and n ± 3 positions. Thus there appears to be a bias for the placement of proline residues at or near the end of several of the inhibitory peptides. Secondary structure analysis predicted that three of the 10 peptides contained , and the 1-day inhibitor pPep11, or the 2-day inhibitor pPep12, were grown in minimal M9 glycerol media with IPTG added to 1 mm. At < 1-h intervals A 550 readings were taken. Data points for pLAC11, pPep11, and pPep12, are indicated by squares, circles, and diamonds, respectively. a known motif that could potentially form a very stable structure. pPep13, is predicted to be 72% a-helical, pPep10 is predicted to be 45% b-sheet and pPep6 is predicted to contain a hydrophobic membrane spanning domain. According to the algorithms that are commonly used to predict the presence of these motifs in proteins, a randomly generated oligonucleotide such as the one used in our studies would have had no better than a 1 in a 1000 chance of generating the motifs that occurred in these peptides (16±24,30).
Verifying that the inhibitory clones do not function as antisense
To verify that the inhibitory clones which we isolated functioned as expressed peptides and not as antisense RNA or DNA, the insert regions between the BglII and EcoRI sites for ®ve of the inhibitors were recloned into the pLAC11 vector using oligonucleotides which converted the ATG start codon to an ACG codon thus abolishing the start site. In all ®ve cases the new constructs were no longer inhibitory (Table 4) , thus con®rming that it is the encoded peptides that causes the inhibition and not the DNA or transcribed mRNA.
Discussion
We have developed an in vivo approach by which novel synthetic bioactive peptides can be isolated that inhibit the growth of E. coli. In our initial screening of 20,000 potential inhibitory clones, 21 inhibitors were isolated which could be grouped into two classes; 18 1-day inhibitors which were partially inhibitory and prevented the growth of bacteria on minimal plates for 24 h, and 3 2-day inhibitors which were completely inhibitory and prevented the growth of bacteria on minimal plates for 48 h. The 1-day inhibitors were found to inhibit the bacterial growth rate at an average of 25%, and thus inhibited the overall growth of the bacteria by 65%. The 2-day inhibitors were found to inhibit the bacterial growth rate at an average of 75% and thus inhibited the overall growth of the bacteria by 96%.
Two of the most potent 2-day inhibitors proved to be fusion peptides in which the C-terminus of the peptides was fused to the N-terminus of the Rop protein. Given the fact that the Rop protein is known to form an incredibly stable structure (31), Rop could be serving as a stable protein Growth rates for cells containing the induced inhibitors were determined as described in the text and then the percentage inhibition was calculated by comparing these values to the growth rate of cells that contained the induced pLAC11 vector. The averaged values of three independent determinations are shown. Table 3 . Sequence analysis of the insert region from the top 10 anchorless inhibitory clones and the peptides that they are predicted to encode The landmark BglII and EcoRI restriction sites for the insert region are underlined. Because the ends of the oligonucleotide from which these inhibitors were constructed contained these restriction sites, the oligonucleotide was not gel isolated when the libraries were prepared in order to maximize our oligonucleotide yields. Because of this, several of the inhibitory clones were found to contain one (n ± 1) or two (n ± 2) base deletions in the randomized portion of the oligonucleotide.
anchor for these two peptides. The characteristics of the predicted coding regions of the top 10 anchorless inhibitor peptides also proved to be quite interesting. Three of the 10 peptides (30%) contained a proline residue as their last amino acid. According to the genetic code, a randomly generated oligonucleotide such as that used in our studies would only have a 6% chance of placing proline at any one position. This 5-fold bias is striking when one considers the fact that proline has been argued to prevent the ability of peptidases to degrade peptides (32, 33) . Additionally, one of the peptides contained a proline residue at the n ± 2 and n ± 3 positions. Growth rates for cells containing the induced inhibitors or antisense constructs were determined and then the % inhibition calculated by comparing these values to the growth rate of cells that contained the induced pLAC11 vector.
